High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients

Annals of Oncology

Volumn 10, Issue 7, 1999, Pages 795-801

  Cottu, P H ^a   Zelek, L ^a   Extra, J M ^a   Espie, M ^a   Mignot, L ^a   Morvan, F ^a   Marty, M ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Accelerated chemotherapy; Breast neoplasms; Metastatic

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEFIXIME; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOXANTRONE; NAVELBINE; TAMOXIFEN; VINCRISTINE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS;

EID: 0032809599     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008353904351     Document Type: Article

References (33)

1. Parker SL, Tong T, Bolden S et al. Cancer statistics, 1997. CA Cancer J Clin 1997; 47: 5-27.
2. Flamm-Honig S. Hormonal therapy and chemotherapy. In Harris J, Lippmann M, Morrow M et al. (eds): Diseases of the Breast. Philadelphia: Lippincott-Raven 1996.
3. Yamamoto N, Watanabe T, Katsumata N et al. Construction and validation of a pratical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998; 16: 2401-8.
4. Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with curability of leukemia. Cancer Chemother Res 1964; 35: 1-12.
5. Goldie JH, Coldman AJ, Gudaukas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66: 439-49.
6. Gilewski T, Norton L. Cytokinetics and breast cancer chemotherapy. In Harris J, Lippman M, Morrow M et al. (eds): Diseases of the Breast. Philadelphia: Lippincott-Raven 1996; 751-67.
7. Henderson IC, Hayes DF, Gelman R. Dose-response in the treatment of breast cancer: A critical review. J Clin Oncol 1988; 6: 1501-15.
8. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-8.
9. Coukell AJ, Faulds D. Epirubicin. An updated review of its pharmacodynamics and pharmacokinetics properties and therapeutic efficacy in the management of breast cancer. Drugs 1997; 53: 453-82.
10. Coiffier B, Bryon PA, Berger F et al. Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (Protocol LNH-80). J Clin Oncol 1986; 4: 147-53.
11. Extra JM, Rousseau F, Mignot L et al. High-dose induction chemotherapy (HDIC) in breast cancer with metastases (MBC) at diagnosis. Proc Ann Meet Am Soc Clin Oncol 1995; 14: A84.
12. Culine S, Extra JM, Espie M et al. Promising results of bimonthly chemotherapy with high dose cyclophosphamide and epirubicin in induction treatment of inflammatory cancer of the breast. Bull Cancer (Paris) 1993; 80: 994-1000.
13. Rubin P, Cooper RA. Statement of the clinical oncologic problem. In Rubin P (ed): Clinical Oncology (7th edition). Philadelphia: WB Saunders 1993; 1-21.
14. Murphy GP. Response criteria of the USM National Prostatic Cancer Project. Prostate 1980; 1.
15. Gisselbrecht C, Extra JM, Lotz JP et al. Cyclophosphamide/ mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Bone Marrow Transplant 1996; 18: 857-63.
16. Snedecor GW, Cochran WG. Statistical Methods (8th edition). Ames, IA: Iowa State University Press 1989.
17. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
18. Cox DR, Oakes D. Analysis of Survival Data. Chapman and Hall 1984.
19. Jones RB, Holland JF, Bhardwaj S et al. A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 1987; 5:172-7.
20. Boyer MJ, McGeer A, Feld R. Recent advances in the management of infections in cancer patients. Crit Rev Oncol Hematol 1993; 15: 175-90.
21. Vahdat L, Antman K. High-dose chemotherapy with autologous stem-cell support for breast cancer. Curr Opin Hematol 1997; 4: 381-9.
22. Falkson G, Gelman RS, Pandya KJ et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998; 16: 1669-76.
23. Rabinovich M, Vallejo C, Bianco A et al. Development and validation of prognostic models in metastatic breast cancer: A GOCS study. Oncology 1992; 49: 188-95.
24. Venturini M, Bruzzi P, Del Mastro L et al. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 764-73.
25. Falkson G, Gelman R, Falkson CI et al. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: A prospective Eastern Cooperative Oncology Group study. J Clin Oncol 1991; 9: 2153-61.
26. Ejlertsen B, Pfeiffer P, Pedersen D et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 1993; 29A: 527-31.
27. Ardizzoni A, Venturini M, Sertoli MR et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: A randomised study in patients with advanced breast cancer. Br J Cancer 1994; 69: 385-91.
28. Lalisang RI, Wils JA, Nortier HW et al. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyle colony-stimulating factor in advanced breast cancer. J Clin Oncol 1997; 15: 1367-76.
29. Piccart MJ, Bruning P, Wildiers J et al. An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naïve patients with locally advanced or metastatic breast cancer. Ann Oncol 1995; 6: 673-7.
30. Antman KH, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-9.
31. Dieras V, Extra JM, Bellissant E el al. Efficacy and tolerance of vinorelbine and fluorouracile combination as first-line chemotherapy of advanced breast cancer: Results of a phase II study using a sequential group method. J Clin Oncol 1996; 14: 3097-104.
32. Gianni L, Munzone E, Capri G et al. Paclitaxel by three-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer; High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study (See comments). J Clin Oncol 1995; 13: 2688-99.
33. Rodenhuis S, Richel DJ, van der Wall E et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998; 352: 515-21.